Biochemical and molecular mechanisms of action of bisphosphonates

Bone

Volumn 49, Issue 1, 2011, Pages 34-41

  Rogers, Michael J ^a   Crockett, Julie C ^a   Coxon, Fraser P ^a   Mönkkönen, Jukka ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

ApppI; Cholesterol; FPP; GGPP; GTPase; IPP; Mevalonate; Prenylation

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE DERIVATIVE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DRUG METABOLITE; ETIDRONIC ACID; GERANYLTRANSFERASE; GUANOSINE TRIPHOSPHATASE; IBANDRONIC ACID; INCADRONIC ACID; ISOPRENOID; MEVALONIC ACID; PAMIDRONIC ACID; PYROPHOSPHORIC ACID DERIVATIVE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

APOPTOSIS; BIOACCUMULATION; BONE DISEASE; BONE MINERAL; CELL FUNCTION; CELL METABOLISM; CELL SURVIVAL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG TARGETING; DRUG UPTAKE; ENZYME INHIBITION; HUMAN; MOLECULAR BIOLOGY; MONOCYTE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PROTEIN PRENYLATION; REVIEW;

ANIMALS; BONE AND BONES; DIMETHYLALLYLTRANSTRANSFERASE; DIPHOSPHONATES; HUMANS; INTRACELLULAR SPACE; METABOLIC NETWORKS AND PATHWAYS; PROTEIN PRENYLATION;

EID: 79958716455     PISSN: 87563282     EISSN: 87563282     Source Type: Journal    
DOI: 10.1016/j.bone.2010.11.008     Document Type: Review

References (100)

1. Roelofs A.J., Coxon F.P., Ebetino F.H., Lundy M.W., Henneman Z.J., Nancollas G.H., et al. Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo. J Bone Miner Res 2010, 25:606-616.
2. Coxon F.P., Thompson K., Roelofs A.J., Ebetino F.H., Rogers M.J. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone 2008, 42:848-860.
3. Roelofs A.J., Jauhiainen M., Mönkkönen H., Rogers M.J., Mönkkönen J., Thompson K. Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 2009, 144:245-250.
4. Roelofs A.J., Thompson K., Ebetino F.H., Rogers M.J., Coxon F.P. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des 2010, 16:2950-2960.
5. Thompson K., Rogers M.J., Coxon F.P., Crockett J.C. Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis. Mol Pharmacol 2006, 1624-1632.
6. Klein G., Martin J.-B., Satre M. Methylenediphosphonate, a metabolic poison in Dictyostelium discoideum. 31P NMR evidence for accumulation of adenosine 5'-(beta, gamma-methylenetriphosphate) and diadenosine 5',5'''-P1,P4-(P2,P3-methylenetetraphosphate). Biochemistry 1989, 27:1897-1901.
7. Rogers M.J., Russell R.G.G., Blackburn G.M., Williamson M.P., Watts D.J. Metabolism of halogenated bisphosphonates by the cellular slime mould Dictyostelium discoideum. Biochem Biophys Res Commun 1992, 189:414-423.
8. Rogers M.J., Ji X., Russell R.G., Blackburn G.M., Williamson M.P., Bayless A.V., et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J 1994, 303:303-311.
9. Pelorgeas S., Martin J.B., Satre M. Cytotoxicity of dichloromethane diphosphonate and of 1-hydroxyethane-1,1-diphosphonate in the amoebae of the slime mould Dictyostelium discoideum. A 31P NMR study. Biochem Pharmacol 1992, 44:2157-2163.
10. Rogers M.J., Xiong X., Brown R.J., Watts D.J., Russell R.G., Bayless A.V., et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995, 47:398-402.
11. Rogers M.J., Brown R.J., Hodkin V., Blackburn G.M., Russell R.G.G., Watts D.J. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun 1996, 224:863-869.
12. Frith J.C., Mönkkönen J., Blackburn G.M., Russell R.G., Rogers M.J. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997, 12:1358-1367.
13. Benford H.L., Frith J.C., Auriola S., Mönkkönen J., Rogers M.J. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999, 56:131-140.
14. Auriola S., Frith J., Rogers M.J., Koivuniemi A., Mönkkönen J. Identification of adenine nucleotide-containing metabolites of bisphosphonate drugs using ion-pair liquid chromatography-electrospray mass spectrometry. J Chrom B 1997, 704:187-195.
15. Sillero M.A., de Diego A., Silles E., Perez-Zuniga F., Sillero A. Synthesis of bisphosphonate derivatives of ATP by T4 RNA ligase. FEBS Lett 2006, 580:5723-5727.
16. Frith J.C., Mönkkönen J., Auriola S., Mönkkönen H., Rogers M.J. The molecular mechanism of action of the anti-resorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arth Rheum 2001, 44:2201-2210.
17. Mönkkönen H., Rogers M.J., Makkonen N., Niva S., Auriola S., Mönkkönen J. The cellular uptake and metabolism of clodronate in RAW 264 macrophages. Pharm Res 2001, 18:1550-1555.
18. Flanagan A.M., Chambers T.J. Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone. Bone Miner 1989, 6:33-43.
19. Schenk R., Merz W.A., Muhlbauer R., Russell R.G.G., Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tiss Res 1973, 11:196-214.
20. Selander K., Lehenkari P., Vaananen H.K. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tiss Int 1994, 55:368-375.
21. Hughes D.E., Wright K.R., Uy H.L., Sasaki A., Yoneda T., Roodman G.D., et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 1995, 10:1478-1487.
22. Selander K.S., Mönkkönen J., Karhukorpi E.K., Harkonen P., Hannuniemi R., Vaananen H.K. Characteristics of clodronate-induced apoptosis in osteoclasts and macrophages. Mol Pharmacol 1996, 50:1127-1138.
23. Hiroi-Furuya E., Kameda T., Hiura K., Mano H., Miyazawa K., Nakamaru Y., et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 1999, 64:219-223.
24. Lehenkari P.P., Kellinsalmi M., Napankangas J.P., Ylitalo K.V., Mönkkönen J., Rogers M.J., et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 2002, 61:1255-1262.
25. Benford H.L., McGowan N.W., Helfrich M.H., Nuttall M.E., Rogers M.J. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 2001, 28:465-473.
26. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat Med 2000, 6:513-519.
27. Reszka A.A., Halasy-Nagy J.M., Masarachia P.J., Rodan G.A. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 1999, 274:34967-34973.
28. Halasy-Nagy J.M., Rodan G.A., Reszka A.A. Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis. Bone 2001, 29:553-559.
29. Sutherland K.A., Rogers H.L., Tosh D., Rogers M.J. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009, 11:R58.
30. Zhang Q., Badell I.R., Schwarz E.M., Boulukos K.E., Yao Z., Boyce B.F., et al. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2. Arthritis Rheum 2005, 52:2708-2718.
31. Amin D., Cornell S.A., Gustafson S.K., Needle S.J., Ullrich J.W., Bilder G.E., et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res 1992, 33:1657-1663.
32. Amin D., Cornell S.A., Perrone M.H., Bilder G.E. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Arzneim Forsch 1996, 46:759-762.
33. Rogers M.J., Chilton K.M., Coxon F.P., Lawry J., Smith M.O., Suri S., et al. Bisphosphonates induce apoptosis in mouse macrophage-like cells in vitro by a nitric oxide-independent mechanism. J Bone Miner Res 1996, 11:1482-1491.
34. Coxon F.P., Benford H.L., Russell R.G.G., Rogers M.J. Protein synthesis is required for caspase activation and induction of apoptosis by bisphosphonate drugs. Mol Pharmacol 1998, 54:631-638.
35. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
36. Roskoski R. Protein prenylation: a pivotal posttranslational process. Biochem Biophys Res Commun 2003, 303:1-7.
37. Zhang F.L., Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Ann Rev Biochem 1996, 65:241-269.
38. Rogers M.J. New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 2003, 9:2643-2658.
39. Sinensky M. Recent advances in the study of prenylated proteins. Biochim Biophys Acta 2000, 1484:93-106.
40. Dunford J.E., Rogers M.J., Ebetino F.H., Phipps R.J., Coxon F.P. Inhibition of protein prenylation by bisphosphonates causes sustained activation of Rac, Cdc42 and Rho GTPases. J Bone Miner Res 2006, 21:684-694.
41. Luckman S.P., Hughes D.E., Coxon F.P., Russell R.G.G., Rogers M.J. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998, 13:581-589.
42. Sato M., Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res 1990, 5:31-40.
43. Breuil V., Cosman F., Stein L., Horbert W., Nieves J., Shen V., et al. Human osteoclast formation and activity in vitro: effects of alendronate. J Bone Miner Res 1998, 13:1721-1729.
44. Carano A., Teitelbaum S.L., Konsek J.D., Schlesinger P.H., Blair H.C. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990, 85:456-461.
45. Sato M., Grasser W., Endo N., Akins R., Simmons H., Thompson D.D., et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 1991, 88:2095-2105.
46. Coxon F.P., Helfrich M.H., van't Hof R.J., Sebti S.M., Ralston S.H., Hamilton A.D., et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 2000, 15:1467-1476.
47. Bergstrom J.D., Bostedor R.G., Masarachia P.J., Reszka A.A., Rodan G. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 2000, 373:231-241.
48. Staal A., Frith J.C., French M.H., Swartz J., Gungor T., Harrity T.W., et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res 2003, 18:88-96.
49. Fisher J.E., Rodan G.A., Reszka A.A. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway. Endocrinology 2000, 141:4793-4796.
50. Osborne T.F., Espenshade P.J. Evolutionary conservation and adaptation in the mechanism that regulates SREBP action: what a long, strange tRIP it's been. Genes Dev 2009, 23:2578-2591.
51. Coxon F.P., Rogers M.J. The role of prenylated small GTP-binding proteins in the regulation of osteoclast function. Calcif Tissue Int 2003, 72:80-84.
52. Ory S., Brazier H., Pawlak G., Blangy A. Rho GTPases in osteoclasts: orchestrators of podosome arrangement. Eur J Cell Biol 2008, 87:469-477.
53. Zhao H., Laitala-Leinonen T., Parikka V., Vaananen H.K. Downregulation of small gtpase rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 2001, 276:39295-39302.
54. Pavlos N.J., Xu J., Riedel D., Yeoh J.S., Teitelbaum S.L., Papadimitriou J.M., et al. Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 2005, 25:5253-5269.
55. Coxon F.P., Helfrich M.H., Larijani B., Muzylak M., Dunford J.E., Marshall D., et al. Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages. J Biol Chem 2001, 276:48213-48222.
56. Glantschnig H., Fisher J.E., Wesolowski G., Rodan G.A., Reszka A.A. M-CSF, TNFalpha and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase. Cell Death Differ 2003, 10:1165-1177.
57. Weinstein R.S., Roberson P.K., Manolagas S.C. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009, 360:53-62.
58. Jain N., Weinstein R.S. Giant osteoclasts after long-term bisphosphonate therapy: diagnostic challenges. Nat Rev Rheumatol 2009, 5:341-346.
59. Fisher J.E., Rogers M.J., Halasy J.M., Luckman S.P., Hughes D.E., Masarachia P.J., et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 1999, 96:133-138.
60. van Beek E., Lowik C., Van der Pluijm G., Papapoulos S. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: a clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Miner Res 1999, 14:722-729.
61. Houten S.M., Wanders R.J., Waterham H.R. Biochemical and genetic aspects of mevalonate kinase and its deficiency. Biochim Biophys Acta 2000, 1529:19-32.
62. Mandey S.H., Schneiders M.S., Koster J., Waterham H.R. Mutational spectrum and genotype-phenotype correlations in mevalonate kinase deficiency. Hum Mutat 2006, 27:796-802.
63. Houten S.M., Schneiders M.S., Wanders R.J., Waterham H.R. Regulation of isoprenoid/cholesterol biosynthesis in cells from mevalonate kinase-deficient patients. J Biol Chem 2003, 278:5736-5743.
64. Mandey S.H., Kuijk L.M., Frenkel J., Waterham H.R. A role for geranylgeranylation in interleukin-1beta secretion. Arthritis Rheum 2006, 54:3690-3695.
65. Kuijk L.M., Beekman J.M., Koster J., Waterham H.R., Frenkel J., Coffer P.J. HMG-CoA reductase inhibition induces IL-1beta release through Rac1/PI3K/PKB-dependent caspase-1 activation. Blood 2008, 112:3563-3573.
66. van Beek E., Pieterman E., Cohen L., Lowik C., Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1999, 255:491-494.
67. Keller R.K., Fliesler S.J. Mechanism of aminobisphosphonate action: characterization of alendronate inhibition of the isoprenoid pathway. Biochem Biophys Res Commun 1999, 266:560-563.
68. Dunford J.E., Thompson K., Coxon F.P., Luckman S.P., Hahn F.M., Poulter C.D., et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296:235-242.
69. Thompson K., Dunford J.E., Ebetino F.H., Rogers M.J. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem Biophys Res Commun 2002, 290:869-873.
70. Kavanagh K.L., Dunford J.E., Bunkoczi G., Russell R.G., Oppermann U. The crystal structure of human geranylgeranyl pyrophosphate synthase reveals a novel hexameric arrangement and inhibitory product binding. J Biol Chem 2006, 281:22004-22012.
71. Dunford J.E., Kwaasi A.A., Rogers M.J., Barnett B.L., Ebetino F.H., Russell R.G., et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 2008, 51:2187-2195.
72. Rogers M.J., Watts D.J., Russell R.G., Ji X., Xiong X., Blackburn G.M., et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res 1994, 9:1029-1039.
73. Szabo C.M., Martin M.B., Oldfield E. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs. J Med Chem 2002, 45:2894-2903.
74. Grove J.E., Brown R.J., Watts D.J. The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase. J Bone Miner Res 2000, 15:971-981.
75. Ory B., Moriceau G., Trichet V., Blanchard F., Berreur M., Redini F., et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med 2008, 12:928-941.
76. Salomo M., Jurlander J., Nielsen L.B., Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. Br J Haematol 2003, 122:202-210.
77. Levy M.E., Parker R.A., Ferrell R.E., Zmuda J.M., Greenspan S.L. Farnesyl diphosphate synthase: a novel genotype association with bone mineral density in elderly women. Maturitas 2007, 57:247-252.
78. Montalvetti A., Bailey B.N., Martin M.B., Severin G.W., Oldfield E., Docampo R. Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase. J Biol Chem 2001, 276:33930-33937.
79. Martin M.B., Sanders J.M., Kendrick H., Luca-Fradley K., Lewis J.C., Grimley J.S., et al. Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem 2002, 45:2904-2914.
80. Martin M.B., Grimley J.S., Lewis J.C., Heath H.T., Bailey B.N., Kendrick H., et al. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy. J Med Chem 2001, 44:909-916.
81. Montalvetti A., Fernandez A., Sanders J.M., Ghosh S., Van Brussel E., Oldfield E., et al. Farnesyl pyrophosphate synthase is an essential enzyme in Trypanosoma brucei. In vitro RNA interference and in vivo inhibition studies. J Biol Chem 2003, 278:17075-17083.
82. Clezardin P., Ebetino F.H., Fournier P.G. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 2005, 65:4971-4974.
83. Luckman S.P., Coxon F.P., Ebetino F.H., Russell R.G.G., Rogers M.J. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res 1998, 13:1668-1678.
84. Kavanagh K., Guo K., Dunford J.E., Wu X., Knapp S., Ebetino F.H., et al. The molecular mechanism of nitrogen-containing bisphosphonates as anti-osteoporosis drugs: crystal structure and inhibition of farnesyl pyrophosphate synthase. Proc Natl Acad Sci USA 2006, 103:7829-7834.
85. Rondeau J.M., Bitsch F., Geiser M., Hemmig R., Kroemer M., Lehmann S., et al. Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. J Med Chem 2006, 1:267-273.
86. Coxon F.P., Ebetino F.H., Mules E.H., Seabra M.C., McKenna C.E., Rogers M.J. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo. Bone 2005, 37:349-358.
87. Baron R.A., Tavare R., Figueiredo A.C., Blazewska K.M., Kashemirov B.A., McKenna C.E., et al. Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase. J Biol Chem 2009, 284:6861-6868.
88. McKenna C.E., Kashemirov B.A., Blazewska K.M., Mallard-Favier I., Stewart C.A., Rojas J., et al. Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid. J Med Chem 2010, 53:3454-3464.
89. Fournier P.G., Daubine F., Lundy M.W., Rogers M.J., Ebetino F.H., Clezardin P. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Cancer Res 2008, 68:8945-8953.
90. Jahnke W., Rondeau J.M., Cotesta S., Marzinzik A., Pelle X., Geiser M., et al. Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. Nat Chem Biol 2010, 6:660-666.
91. Varela I., Pereira S., Ugalde A.P., Navarro C.L., Suarez M.F., Cau P., et al. Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 2008, 14:767-772.
92. Thompson K., Rogers M.J. Statins prevent bisphosphonate-induced gamma, delta-T-cell proliferation and activation in vitro. J Bone Miner Res 2004, 19:278-288.
93. Gober H.J., Kistowska M., Angman L., Jeno P., Mori L., De Libero G. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003, 197:163-168.
94. Thompson K., Roelofs A.J., Jauhiainen M., Mönkkönen H., Mönkkönen J., Rogers M.J. Activation of gammadelta T cells by bisphosphonates. Adv Exp Med Biol 2010, 658:11-20.
95. Mönkkönen H., Kuokkanen J., Holen I., Evans A., Lefley D.V., Jauhiainen M., et al. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth. Anticancer Drugs 2008, 19:391-399.
96. Räikkönen J., Crockett J.C., Rogers M.J., Mönkkönen H., Auriola S., Mönkkönen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Br J Pharmacol 2009, 157:427-435.
97. Coscia M., Quaglino E., Iezzi M., Curcio C., Pantaleoni F., Riganti C., et al. Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcino-genesis by targeting the mevalonate pathway. J Cell Mol Med 2010, 14:2803-2815.
98. Mönkkönen H., Auriola S., Lehenkari P., Kellinsalmi M., Hassinen I.E., Vepsalainen J., et al. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 2006, 147:437-445.
99. Jauhiainen M., Mönkkönen H., Räikkönen J., Mönkkönen J., Auriola S. Analysis of endogenous ATP analogs and mevalonate pathway metabolites in cancer cell cultures using liquid chromatography-electrospray ionization mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009, 877:2967-2975.
100. Mitrofan L.M., Pelkonen J., Mönkkönen J. The level of ATP analog and isopentenyl pyrophosphate correlates with zoledronic acid-induced apoptosis in cancer cells in vitro. Bone 2009, 45:1153-1160.